Literature DB >> 7977370

Identification of a frequent pseudodeficiency mutation in the fumarylacetoacetase gene, with implications for diagnosis of tyrosinemia type I.

H Rootwelt1, E Brodtkorb, E A Kvittingen.   

Abstract

In healthy individuals, fumarylacetoacetase (FAH) activities close to the range found in hereditary tyrosinemia type 1 (HT1) patients indicated the existence of a "pseudodeficiency" allele. In an individual homozygous for pseudodeficiency of FAH and in three HT1 families also carrying the pseudodeficiency allele, western blotting of fibroblast extracts showed that the pseudodeficiency allele gave very little immunoreactive FAH protein, whereas northern analysis revealed a normal amount of FAH mRNA. Sequencing revealed an identical mutation, C1021-->T (Arg341Trp), in all the pseudodeficiency alleles. Site-directed mutagenesis and expression in a rabbit reticulocyte lysate system demonstrated that the C1021-->T mutation gave reduced FAH activity and reduced amounts of the full-length protein. Bs1EI restriction digestion of PCR products distinguished between the normal and the mutated sequences. Among 516 healthy volunteers of Norwegian origin, the C1021-->T mutation was found in 2.2% of the alleles. Testing for the C1021-->T mutation may solve the problem of prenatal diagnosis and carrier detection in families with compound heterozygote genotypes for HT1 and pseudodeficiency.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7977370      PMCID: PMC1918441     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  23 in total

1.  Bidirectional solid-phase sequencing of in vitro-amplified plasmid DNA.

Authors:  T Hultman; S Bergh; T Moks; M Uhlén
Journal:  Biotechniques       Date:  1991-01       Impact factor: 1.993

2.  Direct PCR from CVS and blood lysates for detection of cystic fibrosis and Duchenne muscular dystrophy deletions.

Authors:  M E Balnaves; S Nasioulas; H H Dahl; S Forrest
Journal:  Nucleic Acids Res       Date:  1991-03-11       Impact factor: 16.971

3.  Arylsulfatase A pseudodeficiency: loss of a polyadenylylation signal and N-glycosylation site.

Authors:  V Gieselmann; A Polten; J Kreysing; K von Figura
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

4.  T7 DNA polymerase in automated dideoxy sequencing.

Authors:  T Kristensen; H Voss; C Schwager; J Stegemann; B Sproat; W Ansorge
Journal:  Nucleic Acids Res       Date:  1988-04-25       Impact factor: 16.971

5.  Concentrations of succinylacetone after homogentisate and tyrosine loading in healthy individuals with low fumarylacetoacetase activity.

Authors:  E A Kvittingen; J V Leonard; B R Pettit; G S King
Journal:  Clin Chim Acta       Date:  1985-11-15       Impact factor: 3.786

6.  The occurrence of hepatoma in the chronic form of hereditary tyrosinemia.

Authors:  A G Weinberg; C E Mize; H G Worthen
Journal:  J Pediatr       Date:  1976-03       Impact factor: 4.406

7.  Type I tyrosinemia: lack of immunologically detectable fumarylacetoacetase enzyme protein in tissues and cell extracts.

Authors:  R Berger; H Van Faassen; J W Taanman; H De Vries; E Agsteribbe
Journal:  Pediatr Res       Date:  1987-10       Impact factor: 3.756

8.  Deficiency of fumarylacetoacetase without hereditary tyrosinemia.

Authors:  E A Kvittingen; A L Børresen; O Stokke; C B van der Hagen; S O Lie
Journal:  Clin Genet       Date:  1985-06       Impact factor: 4.438

9.  The pre- and post-natal diagnosis of tyrosinemia type I and the detection of the carrier state by assay of fumarylacetoacetase.

Authors:  E A Kvittingen; E Brodtkorb
Journal:  Scand J Clin Lab Invest Suppl       Date:  1986

10.  Novel splice, missense, and nonsense mutations in the fumarylacetoacetase gene causing tyrosinemia type 1.

Authors:  H Rootwelt; R Berger; G Gray; D A Kelly; T Coşkun; E A Kvittingen
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

View more
  5 in total

1.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

Review 2.  Current strategies for the treatment of hereditary tyrosinemia type I.

Authors:  Merja Ashorn; Sari Pitkänen; Matti K Salo; Markku Heikinheimo
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

3.  Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship.

Authors:  J K Ploos van Amstel; A J Bergman; E A van Beurden; J F Roijers; T Peelen; I E van den Berg; B T Poll-The; E A Kvittingen; R Berger
Journal:  Hum Genet       Date:  1996-01       Impact factor: 4.132

4.  A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation.

Authors:  N Dreumont; J A Poudrier; A Bergeron; H L Levy; F Baklouti; R M Tanguay
Journal:  BMC Genet       Date:  2001-06-29       Impact factor: 2.797

5.  Mildly elevated succinylacetone and normal liver function in compound heterozygotes with pathogenic and pseudodeficient FAH alleles.

Authors:  Hao Yang; Francis Rossignol; Denis Cyr; Rachel Laframboise; Shu Pei Wang; Jean-François Soucy; Marie-Thérèse Berthier; Yves Giguère; Paula J Waters; Grant A Mitchell
Journal:  Mol Genet Metab Rep       Date:  2017-12-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.